Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast Cancer

Authors

Hope S Rugo
Christine L Crossno
Yaron B Gesthalter
Kristen Kelley
Heather B Moore
Mothaffar F Rimawi
Kelly E Westbrook
Saundra S Buys

Publication Date

8-1-2023

Journal

JCO Oncology Practice

DOI

10.1200/OP.22.00480

PMID

37207306

PMCID

PMC10424906

PubMedCentral® Posted Date

5-19-2023

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes

Keywords

Humans, Female, Breast Neoplasms, Antibodies, Monoclonal, Humanized, Immunoconjugates, Lung Diseases, Interstitial, Pneumonia

Abstract

Trastuzumab deruxtecan (T-DXd) is an antibody drug conjugate with a topoisomerase I payload that targets the human epidermal growth factor receptor 2 (HER2). T-DXd is approved for patients with previously treated HER2-positive or HER2-low (immunohistochemistry [IHC] 1+ or IHC 2+/ISH-) metastatic/unresectable breast cancer (BC). In a second-line HER2-positive metastatic BC (mBC) population (DESTINY-Breast03 [ClinicalTrials.gov identifier: NCT03529110]), T-DXd demonstrated significantly improved progression-free survival (PFS) over ado-trastuzumab emtansine (12-month rate: 75.8%

Comments

This article has been corrected. See JCO Oncol Pract. 2024 Mar 20;20(6):872. See "Detecting and Managing T-DXd-Related Interstitial Lung Disease: The Five "S" Rules." on page OP2300097.